Asterias Biotherapeutics Receives $11.7M in Proceeds from Exercise of Warrants
Benzinga Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that all outstanding common share purchase warrants originally issued in June 2014 were exercised prior to … |